Global Neurothrombectomy Devices Market 2023-2030

Global Neurothrombectomy Devices Market 2023-2030

Global Neurothrombectomy Devices Market Size, Share & Trends Analysis Report by Product (Clot Retrievers Devices, Aspiration Devices, and Vascular Snares), and by End-User (Hospitals and Emergency Clinics), Forecast Period (2023-2030)

The global neurothrombectomy devices market is anticipated to grow at a CAGR of 7.3% during the forecast period (2023-2030). The growth of this market is attributed to the increasing incidences of acute ischemic stroke globally, rising adoption of unhealthy lifestyles and increasing awareness of the disorder among the population is fueling market growth. According to the World Stroke Organization Fact Sheet 2022, Prevalence for all Ischemic stroke for all ages were 7,630,803. The crude rate per 100,000 per year was 94.5, and Age-adjusted rate per 100,000, per year was 98.6. There are over 7.6 million new ischemic strokes each year. Globally, over 62.0% of all incident strokes are ischemic strokes. Of which, each year, over 11% of all ischemic strokes occur in people 15-49 years of age, over 58.0% of all ischemic strokes occur in people aged under 70 years, 45.0% of all ischemic strokes occur in men, and 55.0% of all ischemic strokes occur in women. In addition, in November 2022, the article “Senior Population Statistics: A Portrait of Aging Americans”, reported 54.1 million adults or 16.3% of the US population are seniors including aged 65 or older. The senior population is expected to rise to 22.0% by 2040 and 25.0% by 2060.

Segmental Outlook

The global neurothrombectomy devices market is segmented based on product and end-user. Based on the product, the market is sub-segmented into clot retrievers devices, aspiration devices, and vascular snares. Further, based on end-user, the market is bifurcated into hospitals and emergency clinics. Among the end-user, the hospitals sub-segment is anticipated to hold the largest market share during the forecast period. The large share of this segment is credited to the lower costs, higher efficiency, and availability.

The Clot Retrievers Devices Sub-Segment is Anticipated to Hold a Considerable Share of the Global Neurothrombectomy Devices Market

Among the products, clot retrievers devices sub-segments expected to grow over the forecast period. The segment is driven by the owing to rising prevalence of AIS and an increasing number of product launches by key market players. It is majorly used for removing blood clots from the cerebral arteries. Furthermore, the use of clot retrievers has increased in elderly patients (aged 55 to 65) owing to growing incidence of stroke. Hence, growing cases of targeted disorder are driving segment growth. In addition, the growing number of FDA approvals is accelerating the segmental growth. In June 2023, Innova Vascular, Inc. received US Food and Drug Administration (FDA) 510(k) clearance for its Laguna Clot Retriever™ System and its Malibu Aspiration Catheter™ System for use in the peripheral vasculature. The two new devices are collectively known as the Laguna Thrombectomy System.

Regional Outlook

The global neurothrombectomy devices market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, the Asia-Pacific region is anticipated to grow considerably over the forecast period. This is owing to the growing demand for neurothrombectomy devices, increasing geriatric population, the rising healthcare expenditure, and increasing incidences of cardiovascular diseases (CVDs) and heart related conditions.

The North America Region is Expected to Grow at a Significant CAGR in the Global Neurothrombectomy Devices Market

North America is expected to hold a prominent share in the neurothrombectomy devices market during the forecast period. The significant factors fueling the North America market including growing technological advancements in neurothrombectomy devices, rising incidences of strokes, increasing geriatric population, and favorable government regulations regarding monitoring devices. According to the United States Census Bureau, the older population increased by 50.9 million, from 4.9 million (or 4.7% of the total US population) in 1920 to 55.8 million (16.8%) in 2020. In 2020, about 1 in 6 people in the US were age 65 and over. In 1920, this proportion was less than 1 in 20. In addition, the demand for neurothrombectomy devices, and other technological advancements to ensure improved CVD prevention and control is likely to rise in the future. According to the American Heart Association, CVDs remains as the leading cause of death in the US, accounted for 928,741 deaths in the year 2020. Additionally, the increasing number of heart-related disorders and technological advancements are further driving the market in the region. In 2020 in the US, coronary heart disease (CHD) was the leading cause (41.2%) of deaths attributable to CVD in the US, followed by stroke (17.3%).

Market Players Outlook

The major companies serving the global neurothrombectomy devices market includes Acandis GmbH, Medtronic plc, Penumbra, Inc., and Stryker Corp., among others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in July 2023, RenovoRx, Inc., a Los Altos, California-based clinical-stage biopharmaceutical company developing targeted combination therapies, and Imugene Ltd, a clinical-stage immuno-oncology company headquartered in Sydney, Australia, entered a strategic research collaboration to optimize the delivery of Imugene’s oncolytic virus therapy with RenovoRx’s trans arterial micro perfusion (TAMP) therapy platform for the treatment of difficult-to-access tumors. As part of the collaboration, Imugene and RenovoRx will investigate the ability to administer Imugene’s CF33 oncolytic virus technology with RenovoRx’s TAMP therapy platform.

The Report Covers

Market value data analysis of 2022 and forecast to 2030.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global neurothrombectomy devices market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying ‘who-stands-where’ in the market.